Department of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland.
Systems Biology Program, Life Science Zürich Graduate School, Zürich, Switzerland.
Cell Rep Methods. 2022 Jan 14;2(1):100154. doi: 10.1016/j.crmeth.2021.100154. eCollection 2022 Jan 24.
Existing approaches to therapeutic gene transfer are marred by the transient nature of gene expression following non-integrative gene delivery and by safety concerns due to the random mechanism of viral-mediated genomic insertions. The disadvantages of these methods encourage future research in identifying human genomic sites that allow for durable and safe expression of genes of interest. We conducted a bioinformatic search followed by the experimental characterization of human genomic sites, identifying two that demonstrated the stable expression of integrated reporter and therapeutic genes without malignant changes to the cellular transcriptome. The cell-type agnostic criteria used in our bioinformatic search suggest widescale applicability of identified sites for engineering of a diverse range of tissues for clinical and research purposes, including modified T cells for cancer therapy and engineered skin to ameliorate inherited diseases and aging. In addition, the stable and robust levels of gene expression from identified sites allow for the industry-scale biomanufacturing of proteins in human cells.
现有的治疗性基因转移方法存在一些局限性,例如非整合基因传递后基因表达的短暂性,以及由于病毒介导的基因组插入的随机机制而产生的安全性问题。这些方法的缺点促使未来的研究致力于确定允许感兴趣的基因持久和安全表达的人类基因组位点。我们进行了生物信息学搜索,随后对人类基因组位点进行了实验表征,确定了两个位点能够稳定表达整合的报告基因和治疗基因,而细胞转录组没有发生恶性变化。我们在生物信息学搜索中使用的细胞类型不可知标准表明,所鉴定的位点可广泛应用于为临床和研究目的设计多种组织,包括用于癌症治疗的修饰 T 细胞和用于改善遗传性疾病和衰老的工程化皮肤。此外,所鉴定的位点具有稳定和强大的基因表达水平,可在人类细胞中进行工业规模的蛋白质生物制造。